Earnings call Dr. Lal PathLabs reported FY25 revenue of ₹2,461 crore, up 10.5% YoY, with PAT rising 35.9% to ₹492 crore (including a one-time tax benefit). Q4 margins expanded, but FY26 guidance ...
(Reuters) -Dr Lal Path Labs, India's largest diagnostics firm by revenue, reported fourth-quarter profit above expectations on Friday as strong demand for its bundled test packages lifted growth amid ...
Jan 30 (Reuters) - India's Dr Lal Path Labs (DLPA.NS), opens new tab reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its ...
Shares of Dr Lal Pathlabs fell 5% on Friday after June 2023 results. Shares of Dr Lal Pathlabs fell 5% on Friday after June 2023 results. Kotak Institutional Equities has a 'sell' rating with FV of Rs ...
Add Yahoo as a preferred source to see more of our stories on Google. (Refiles to remove extraneous link in paragraph 1) April 30 (Reuters) - Dr Lal Path Labs reported a 15.5% drop in fourth-quarter ...
Om Prakash Manchanda, managing director of Dr Lal Pathlabs,, says the company doesn't want to lose on top-of-the-mind recall. Dr Lal Pathlabs Ltd has a storied history almost as old as independent ...
ET Now on MSN
Dr Lal Path Labs dividend 2026: Rs 4 per share payout in Q4 results FY26 - Record date on June 26
Dr Lal Path Labs Dividend 2026: The BSE 500 company on April 30 announced its Q4 quarterly earnings for financial year ...
Earnings call Dr. Lal PathLabs reported 10.7% YoY revenue growth and 19.3% PAT growth in Q3 FY25, despite no price increases. The company is executing a multi-pronged strategy of geographic expansion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results